JOYN Advisors’s Charles River Laboratories CRL Stock Holding History

JOYN Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-435	Closed	-$49K	–	387
2018 Q4	$49K	Sell	435 -10	-2%	-$1.25K	0.01%	346
2018 Q3	$60K	Sell	445 -12	-3%	-$1.48K	0.01%	350
2018 Q2	$51K	Sell	457 -216	-32%	-$23.4K	0.01%	386
2018 Q1	$72K	Buy	+673	New	+$72.5K	0.02%	363

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

JOYN Advisors's CRL Position: Q1 2019 in Review

JOYN Advisors sold out of Charles River Laboratories (CRL) in Q1 2019, closing a stake of 435 shares — an estimated $49K sold.

JOYN Advisors first reported a position in CRL in Q1 2018 and held it in 4 quarters. The position peaked at $72K in Q1 2018. 409 funds tracked by Wall St. Rank hold CRL as of Q1 2019.

JOYN Advisors reported no remaining Charles River Laboratories position as of Q1 2019 after selling out during the quarter.
JOYN Advisors sold 435 Charles River Laboratories shares in Q1 2019, an estimated $49K.
JOYN Advisors first reported a position in Charles River Laboratories in Q1 2018 and held it in 4 quarters.
JOYN Advisors's Charles River Laboratories position peaked at $72K in Q1 2018.
409 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2019.

Based on JOYN Advisors's 13F filing for Q1 2019, filed 9 May 2019.